GLP-1 drug costs on TikTok: what the sticker shock videos miss

What did @myriamestrella8 actually say?

She said she pays $500 a month for a weight loss injection, and that brand-name Mounjaro would have cost her "upwards of $1,000 a month" without insurance coverage. She's asking her audience how much they pay, framing this as a shared financial burden. That's the whole claim: these drugs are expensive, insurance often won't cover them for weight loss, and she found a cheaper alternative.

She doesn't name the cheaper option explicitly, but the price point strongly suggests a compounded version of tirzepatide from a compounding pharmacy, which have become widely available since the FDA placed tirzepatide on its shortage list. She isn't making a medical claim here. She's making a cost complaint. And honestly, she's not wrong to complain.

Does the science back this up?

Yes, the pricing reality she describes is well-documented. The cost figures she cites are accurate, and the insurance coverage gap for GLP-1 medications used for obesity is a recognized policy problem, not an exaggeration.

Brand-name Mounjaro (tirzepatide) has a list price of approximately $1,000 to $1,200 per month in the U.S. without insurance or manufacturer coupons. Eli Lilly's savings card can bring this down for commercially insured patients, but people without qualifying insurance coverage pay close to full price. A 2023 analysis published in JAMA by Sheehan et al. found that fewer than 25% of large employer insurance plans covered GLP-1 medications for obesity as of 2022, even as coverage for type 2 diabetes indications was more common. Medicare Part D was explicitly prohibited from covering weight loss drugs until the Treat and Reduce Obesity Act proposals began gaining traction, and coverage remains inconsistent. The $500 figure she cites aligns with reported market rates for compounded tirzepatide from telehealth platforms and compounding pharmacies, which have ranged from roughly $200 to $600 per month depending on dose and provider.

What did they get wrong (or right)?

She got the pricing reality right. The coverage gap she describes is real and well-supported. Where the video is incomplete, not wrong, is that it doesn't distinguish between brand-name Mounjaro and what she's actually taking, which matters.

Compounded tirzepatide is not the same as FDA-approved Mounjaro. The FDA has been explicit about this. Compounded drugs are not evaluated for safety, efficacy, or manufacturing quality in the same way approved drugs are. The agency issued a warning in 2024 noting reports of adverse events tied to compounded GLP-1 products, including dosing errors. If she's paying $500 for compounded tirzepatide, that's a legitimate option many people choose for cost reasons, but consumers should know they are not getting a verified equivalent of the brand-name product. She doesn't claim they're the same, to be fair. She just doesn't clarify the difference. At 171,000 views, that gap matters.

What should you actually know?

If you're comparing costs for GLP-1 medications, here's what actually affects the number: insurance coverage tier, whether your diagnosis is obesity versus type 2 diabetes, which drug and dose you're on, and whether you're using a brand-name or compounded product.

Brand-name Wegovy (semaglutide for obesity) has a list price around $1,350 per month. Ozempic (semaglutide for diabetes) is approximately $900 per month. Manufacturer savings programs exist, but eligibility is restricted. Compounded versions are cheaper but come with regulatory caveats. In March 2024, the FDA announced it would phase out allowances for compounded semaglutide as shortage designations were resolved, and similar pressure is expected for tirzepatide. A 2024 GoodRx analysis found that patients using telehealth-based compounding platforms paid a median of $250 to $500 monthly for compounded semaglutide, consistent with the range this creator describes for tirzepatide. If cost is your barrier, legitimate options include manufacturer patient assistance programs, state Medicaid expansion depending on your state, and licensed telehealth platforms that prescribe FDA-approved generics or assist with prior authorization. Crowdsourcing your medication decisions from TikTok comments is not one of those options.